Toggle navigation
Home
Search
Services
Blog
Contact
About
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara
Biocryst Pharmaceuticals, Inc., Birmingham, AL, United States
Search 146 grants from Y Babu
Search grants from Biocryst Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Identification of microRNAs responsive to nicotine exposure
Urinary Bladder Dysfunction in Diabetes Mellitus
An Infectious Full Length Transcript of Dengue Virus Type 2
Biomimetic Multifunctional Device for Quantification and Analysis of Circulating Tumor Cells (CTC)
A Coalgebraic Framework for Development and Composition of Hybrid Systems
Recently added grants:
Comparative and functional genomics of C. neoformans
CysLT and P2Y Receptors in Lung Inflammation
Demystifying the antiviral activity of the IgG3+ antibody response
Inducible Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus
An IL-15 superagonist approach to clear the latent viral reservoir
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AR041095-03
Application #
2080467
Study Section
Special Emphasis Panel (ZRG7-SSS-6 (06))
Project Start
1994-02-16
Project End
1996-02-15
Budget Start
1995-04-05
Budget End
1996-02-15
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Biocryst Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
Related projects
NIH 1995
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
NIH 1994
R44 AR
Design of Inhibitors for Complement Protein Factor D
Babu, Y Sudhakara / Biocryst Pharmaceuticals, Inc.
Comments
Be the first to comment on this grant